A New Way to Treat Stubborn Warts: Injecting the HPV Vaccine Directly Into the Warts

456

This method is called warts intralesional immunotherapy. It's different from the usual way of giving the vaccine to prevent HPV infections.

A New Way to Treat Stubborn Warts: Injecting the HPV Vaccine Directly Into the Warts

Intralesional Immunotherapy - A New Method to Treat Stubborn Warts

Doctors have recently started trying a new method to treat these stubborn warts: injecting the HPV vaccine directly into the warts. This method is called intralesional immunotherapy. It's different from the usual way of giving the vaccine as a shot in the muscle, which is meant to prevent HPV infections.

For wart removal or Gardasil 9, which protects against HPV-related cancers for all genders, contact us at info.bkk@pulse-clinic.com or any of the following platforms:

 

 +66 65 237 1936    @PULSEClinic   PulseClinic

 

Treatment for Cutaneous Warts


Cutaneous warts, caused by the human papillomavirus (HPV), are a common and often persistent dermatological problem. Traditional treatments include cryotherapy, electrodesiccation and curettage, topical salicylic acid, imiquimod, 5-fluorouracil, and cantharidin. Less frequently, treatments like immunotherapy with diphenylcyclopropenone or squaric acid dibutyl ester, topical/intralesional cidofovir, oral retinoids, and intralesional bleomycin are used. CO2 or pulsed dye lasers, photodynamic therapy, or local hyperthermia can benefit persistent cases. Despite the variety of treatments available, managing recalcitrant warts remains challenging.

 

The Role of Intralesional Immunotherapy


Intralesional immunotherapy has been explored using agents such as candida antigen, mumps antigen, combined measles, mumps, and rubella (MMR) vaccine, tuberculin purified protein derivative, and bacille Calmette-Guerin vaccine. This approach aims to stimulate a local immune response directly at the wart site, enhancing the body's ability to fight the virus.

 

Intralesional HPV Vaccine: A New Approach


The intralesional use of the HPV vaccine has shown significant promise. Recent studies have focused on the clinical effectiveness and safety profile of intralesional administration of the 9-valent HPV vaccine for treating recalcitrant warts.

The 9-valent HPV vaccine covers HPV subtypes 6, 11, 16, 18, 31, 33, 45, 52, and 58 and has demonstrated a good response, with complete clearance in 60% of cases and no evidence of recurrence.

 

Add us on Line and stay in touch.

LINE @pulseclinic

 

Mechanism and Benefits


HPV vaccines contain noninfectious HPV-like particles made from the L1 capsid protein of each HPV subtype. The homology between the L1 capsid proteins of the HPV subtypes responsible for common warts (HPV types 1-4) and those found in the vaccines suggests that cross-immunity may help elicit an immune response against a wide range of HPV subtypes.

The systemic administration of 2-valent and 4-valent HPV vaccines has shown promise in treating common warts. Recently, three case reports documented the routine systemic administration of the 9-valent HPV vaccine, which cleared all existing warts completely.

Comparative studies have found that intralesional injection of HPV vaccines is more beneficial than routine intramuscular administration. For instance, Nofal et al. reported an 81.8% complete clearance rate in patients treated with the intralesional 2-valent HPV vaccine, compared to 63.3% in those receiving the vaccine intramuscularly. These findings suggest that intralesional administration may provide a higher local concentration of the vaccine, enhancing its therapeutic effect.

Immune Response and Long-Term Efficacy


The intralesional HPV vaccine induces a robust cell-mediated immune response. By injecting the vaccine directly into the wart, Th1 cytokines such as interleukin 2 and interferon-gamma are increased, activating cytotoxic and natural killer cells. This response helps eradicate the HPV infection at both injected and noninjected sites. The trauma of the injection itself may also contribute to the immune response.

The long-term immunity induced by HPV vaccines likely explains the lack of recurrences observed in studies. For example, no recurrences were recorded in the present study, or the study by Nofal et al., and only one recurrence was noted in another study using intramuscular vaccination.

 

Safety and Limitations


The primary adverse effect observed with intralesional HPV vaccine administration was transient localized pain at the injection site. No systemic adverse effects were reported. However, the small number of participants and the retrospective nature of some studies highlight the need for more extensive, prospective, double-blind, placebo-controlled studies.

 

Conclusion


Given its safety profile, accessibility, and relatively low cost, the intralesional 9-valent HPV vaccine should be considered a potential therapeutic option for treating recalcitrant cutaneous warts. Further research is needed to establish the optimal treatment regimen and confirm the therapeutic value of this approach.

 

PULSE Clinic Branches


 

Thailand

PULSE Clinic Silom Bangkok info.bkk@pulse-clinic.com  Tel: +66 65237 1936 or WhatsApp or LINE official account 

PULSE Clinic Nana Bangkok info.bkk@pulse-clinic.com   Tel: +66 95915 6385 or WhatsApp or LINE official account 

PULSE Clinic Nana2 Bangkok info.bkk@pulse-clinic.com Tel: +66 99426 6982 or WhatsApp or LINE official account 

PULSE Clinic Sukhumvit 37,info.bkk@pulse-clinic.com  Tel: +66 92497 9353 or WhatsApp or LINE official account 

PULSE Clinic Airport Link Phayathai, Bangkok info.bkk@pulse-clinic.com  Tel : +66842426292

PULSE Clinic Asoke – Executive Health center Asoke, Bangkok info@eu-health.org  Tel :+66 64 742 6528 or WhatsApp or LINE official account 

PULSE Clinic South Pattaya info.bkk@pulse-clinic.com  Tel :+66 62 828 7969 or WhatsApp or LINE official account 

PULSE Clinic North Pattaya info.bkk@pulse-clinic.com Tel :+66 62 828 7969 or WhatsApp or LINE official account 

PULSE Clinic Nimman, Chiang Mai info.cnx@pulse-clinic.com Tel: +66 99479 7168 or WhatsApp or LINE official account 

PULSE Clinic Patong Beach, Phuket info.phuket@pulse-clinic.com  Tel: +66 95261 5282 or WhatsApp or LINE official account 

PULSE Clinic Phuket Town, Phuket info.phuket@pulse-clinic.com  Tel: +66 64059 1495 or WhatsApp or LINE official account 

 

Malaysia

PULSE Clinic Bukit Bintang, Kuala Lumpur info.kl@pulse-clinic.com  Tel: +60321102122, Whatsapp +601165388678

PULSE Clinic Bangsar, Kuala Lumpur info.kl@pulse-clinic.com  Tel: +60321102122, Whatsapp +601165388678

PULSE Clinic George Town, Penang info.pg@pulse-clinic.com+60138039693, Whatsapp +60138039693

 

 Hong Kong

PULSE Clinic Central, Hong Kong info.hk@pulse-clinic.com  Tel: +852 2389 8250

 

 Singapore
PULSE Clinic Tanjong Pagar, Singapore info.sg@pulse-clinic.com  Tel: +65 6974 59190 or WhatsApp 

 

 Philippines 

PULSE Clinic Manila, Philippines info.ph@pulse-clinic.com  Tel: +63 91712454970or WhatsApp or LINE official account 

 

 

We’re here to help


Whatever you’re experiencing, you are not alone. PULSE Social Enterprise is here to help with any concerns or questions you might have about your health.

 

From general wellness to mental well-being to sexual health, we will be sure to give you fast, reliable, and safe diagnosis, treatment, and consultation.

To book an appointment, please email us at info.bkk@pulse-clinic.com or chat with us on your preferred platform.

 +66 65 237 1936  @PulseRx    PULSEClinic

 

Trust PULSE CLINIC to take care of your health like other 45000 people from over 130 countries. We provide discreet professional service with high privacy. Here to help, not to judge.

Book An Appointment NOW